title: Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico.
abstract: BACKGROUND
  Evidence regarding the outcomes of Hispanic women with breast cancer is lacking. We analyzed women with HER2+ disease treated with trastuzumab-based neoadjuvant chemotherapy in Mexico.
  
  
  METHODS
  244 patients were included. Outcomes were compared between patients who achieved pathologic complete response (pCR) (n = 119), or less than pCR (n = 125). Patients with noninvasive (ypT0/is, ypN0) residual disease were also analyzed.
  
  
  RESULTS
  119 (48.8%) patients achieved pCR. pCR was the only factor associated with improved 3 year survival (98.1% vs 92.3%: P = 0.02). Survival was better in patients with ypT0/is, ypN0 response than in those with residual invasive disease (p < 0.01). 3 year survival was 98.1% for patients with pCR and 92.6% for patients with ypTis, ypN0 response (p = 0.64).
  
  
  CONCLUSIONS
  Response rates to trastuzumab based neoadjuvant chemotherapy in Hispanics mimic that of other ethnic groups. This underlines the fact that access to treatment, rather than ethnicity, is the main prognostic factor in this population.
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico; Unit of Biomedical Investigation in Cancer, National Autonomous University of Mexico and National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico; Breast Cancer Center, Instituto Tecnológico de Monterrey, Eugenio Garza Sada Sur 2501, Tecnológico, 64849 Monterrey, NL, Mexico. Electronic address: cynthiavg@gmail.com.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Villarreal-Garza
authors.affiliation: Department of Hemato/Oncology, National Institute of Medical Science and Nutrition, Vasco de Quiroga 15, Sección XVI, Tlalpan, Ciudad de México, Distrito Federal, Mexico. Electronic address: enriquesotopc@yahoo.com.
authors.forename: Enrique
authors.initials: E
authors.lastname: Soto-Perez-de-Celis
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: erikasifuentes@gmail.com.
authors.forename: Erika
authors.initials: E
authors.lastname: Sifuentes
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: ruanosantiago@gmail.com.
authors.forename: Santiago
authors.initials: S
authors.lastname: Ruano
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: fberenice@gmail.com.
authors.forename: Berenice
authors.initials: B
authors.lastname: Baez-Revueltas
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: fuliseslara@yahoo.com.mx.
authors.forename: Fernando
authors.initials: F
authors.lastname: Lara-Medina
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: claudia.arces@hotmail.ca.
authors.forename: Claudia
authors.initials: C
authors.lastname: Arce-Salinas
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: albertooncologia@yahoo.com.mx.
authors.forename: Alberto
authors.initials: A
authors.lastname: Alvarado-Miranda
authors.affiliation: Department of Hemato/Oncology, National Institute of Medical Science and Nutrition, Vasco de Quiroga 15, Sección XVI, Tlalpan, Ciudad de México, Distrito Federal, Mexico. Electronic address: yaninchg@gmail.com.
authors.forename: Yanin
authors.initials: Y
authors.lastname: Chavarri-Guerra
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: bluevox99@hotmail.com.
authors.forename: Claudia
authors.initials: C
authors.lastname: Caro-Sanchez
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: dr.noelcastaneda@gmail.com.
authors.forename: Noel
authors.initials: N
authors.lastname: Castañeda-Soto
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: ebargallo@yahoo.com.
authors.forename: Enrique
authors.initials: E
authors.lastname: Bargallo-Rocha
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico; Unit of Biomedical Investigation in Cancer, National Autonomous University of Mexico and National Cancer Institute, Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, 14080 Ciudad de México, Distrito Federal, Mexico. Electronic address: amohar@incan.edu.mx.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Mohar
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000379:methods; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008408:Mastectomy; D015412:Mastectomy, Segmental; D008800:Mexico; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases; D012074:Remission Induction; D043823:Taxoids / Q000627:therapeutic use; D000068878:Trastuzumab / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab
keywords: Breast cancer; Hispanics; Latin America; Neoadjuvant therapy; Receptor, erbB-2; Trastiuzumab